|Oxygen Biotherapeutics, Inc.|
ONE Copley Parkway
United States - Map
Oxygen Biotherapeutics, Inc., a development stage company, engages in developing biotechnology products that deliver oxygen to target tissues in the body primarily in the United States. It develops Oxycyte, a systemic perfluorocarbon based oil in water emulsion oxygen carrier for use in situations of acute ischemia; and is in Phase II-b clinical trial for the treatment of traumatic brain injury. The company also provides perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. In addition, it offers Dermacyte line of topical cosmetic products that promote the appearance of skin health and other cosmetic benefits; and Wundecyte, a wound-healing gel. It sells Dermacyte through distribution agreements, on-line retailers, and direct sales to physician and medical spa facilities. The company was formerly known as Synthetic Blood International, Inc. and changed its name to Oxygen Biotherapeutics, Inc. in June 2008. Oxygen Biotherapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
|Mr. Michael B. Jebsen CPA,
Chief Financial Officer, Principal Accounting Officer and Treasurer
|Mr. John P. Kelley MBA,
Chief Exec. Officer and Director
|Ms. Ellen T. Corliss ,
Sr. VP of Corp. Communications & Investor Relations
|Ms. Nancy J. M. Hecox ,
Sr. VP of Legal Affairs, Gen. Counsel and Corp. Sec.
| Maria Isabel Tomargo ,
Assistant VP of Marketing & Sales
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|